Imexpharm Corporation

Established in 1977 in Dong Thap Province, Vietnam, Imexpharm is committed to delivering high-quality healthcare solutions through EU-GMP-standard products recognized for their safety, efficacy, and quality. With nearly five decades of continuous growth, Imexpharm has established a solid foundation in research and development, cutting-edge technology, modern infrastructure, and sustainable practices, all driven by its vision “Trusted quality, European standard”. Today, Imexpharm is the No.1 producer of antibiotics in Vietnam and operates the most EU-GMP-certified production lines in the country, with three EU-GMP factory clusters and 12 EU-GMP certified lines. The company has also obtained 28 European MAUs for 11 products, affirming its global competitiveness. In 2024, Imexpharm successfully completed its bonus share issuance, making it the largest listed pharmaceutical company in Vietnam by charter capital. Imexpharm is a trusted contract manufacturing partner for global pharmaceutical leaders such as Sandoz, Sanofi-Aventis, Agimexpharm, Genuone Sciences Inc, and SK. The company is actively expanding into high-value, high-tech segments and advanced dosage forms, including injectables and dispersible tablets, to enhance healthcare accessibility in Vietnam and accelerate export growth across new markets. Guided by the philosophy years later, the lotus still blooms,’ Imexpharm, under strong leadership and with a team of over 1,400 dedicated professionals, remains steadfast in its pursuit of sustainable growth and long-term profitability, actively contributing to Vietnam’s vision of becoming a regional hub for high-value pharmaceutical manufacturing by 2030.